Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 1/2013

01-01-2013 | Research Article

Progressive increase of glucose transporter-3 (GLUT-3) expression in estrogen-induced breast carcinogenesis

Authors: M. A. Kocdor, H. Kocdor, J. S. Pereira, J. E. Vanegas, I. H. Russo, J. Russo

Published in: Clinical and Translational Oncology | Issue 1/2013

Login to get access

Abstract

Introduction

Increased glucose uptake and glycolysis are main metabolic characteristics of malignant cells. A family of glucose transporters (GLUTs) facilitates glucose movement across the plasma membranes in a tumor-specific manner. Glucose transporter-1 (GLUT-1), GLUT-3 and recently GLUT-12, have been previously shown in breast cancer cells and are found to be associated with poor prognosis. In addition, it has been shown that estrogen plays critical roles in GLUT regulation, however, the stage-specific GLUT regulation of mammary carcinogenesis is unclear.

Methods

GLUT expression patterns were investigated in an in vitro–in vivo progressive, estrogen-induced, mammary carcinogenesis model which consisted of four cell lines, with same genetic background. In this model, different stages of tumor initiation and progression are represented, MCF-10F being the normal stage, E2 cells the transformed stage by estrogen, C5 cells, the invasive stage, and T4 cells the tumorigenic stage. In addition, loss of ductulogenesis and solid mass formation in collagen matrix and invasiveness of the cells were counted.

Results

Real time PCR showed that GLUT1 expression was downregulated in MCF10F after treatment with 17β-estradiol (E2), and in the invasive cell type (C5), but not in the tumor cells (T4), which had no changes compared to MCF10F. C5 and T4 cells showed the highest rate of GLUT-3 expression. These cells were also found to be associated with loss of ductulogenesis, solid mass formation and higher invasive capacity, whereas, GLUT-12 was downregulated in C5 and T4 cells.

Conclusion

Estrogen-induced malignant transformation is associated with remarkable and progressive GLUT-3 expression, GLUT-1 re-expression at further stages, as well as GLUT-12 downregulation.
Literature
1.
Devlin TM (2006) Biological membranes: structure and membrane transport. In: Devlin TM (ed) Textbook of biochemistry, 6th edn. Wiley-Liss, Hoboken, NJ, pp 443–487
2.
Lieberman M, Marks AD (2009) Digestion, absorption, and transport of carbohydrates. In: Marks’ basic medical biochemistry a clinical approach, 3rd edn. Wolters Kluwer, LWW, Baltimore MD, pp 499–517
3.
4.
Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (Glut) proteins in cancer. J Cell Physiol 202:654–662PubMedCrossRef
5.
Gatenby RA, Gawlinski ET (2003) The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res 63:3847–3854PubMed
6.
Gillies R, Gatenby RA (2007) Hypoxia and adaptive landscapes in the evaluation of carcinogenesis. Cancer Metastasis Rev 26:311–317PubMedCrossRef
7.
Warburg O (1956) On respiratory impairment in cancer cells. Science 124:269–270PubMed
8.
Hennipman A, van Oirschot BA, Smitz J et al (1988) Glycolytic enzyme activities in breast cancer metastasis. Tumour Biol 9:241–248PubMedCrossRef
9.
Suganuma N, Segade F, Matsuzu K, Bowden DW (2007) Differential expression of facilitative glucose transporters in normal and tumour kidney tissues. BJU Int 99:1143–1149PubMedCrossRef
10.
Medina RA, Owen GI (2002) Glucose transporters: expression, regulation and cancer. Biol Res 35:9–26PubMedCrossRef
11.
Rogers S, Macheda ML, Docherty SE et al (2002) Identification of a novel glucose transporter-like protein GLUT-12. Am J Physiol Endocrinol Metab 282:733–738
12.
Stackhouse BL, Williams H, Berry P et al (2005) Measurement of Glut-1 expression using tissue microarrays to determine a race specific prognostic marker for breast cancer. Breast Cancer Res Treat 93:247–253PubMedCrossRef
13.
Gatenby RA, Smallbone K, Maini PK et al (2007) Cellular adaptations to hypoxia and acidosis during somatic evaluation of breast cancer. Brit J Cancer 97:646–653PubMedCrossRef
14.
Robey IF, Stephen RM, Brown KS et al (2008) Regulation of Warburg effect in early-passage breast cancer cells. Neoplasia 10:745–756PubMed
15.
Fang JS, Gillies RD, Gatenby RA (2008) Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol 18:330–337PubMedCrossRef
16.
Airley RE, Mobasheri A (2007) Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 53:233–256PubMedCrossRef
17.
Ortega AD, Sanchez-Arago M, Giner-Sanchez D et al (2009) Glucose avidity of carcinomas. Cancer Lett 276:125–135PubMedCrossRef
18.
Flier JS, Mueckler MM, Usher P, Lodish HF (1987) Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 235:1492–1495PubMedCrossRef
19.
Gillies RJ, Robey I, Gatenby RA (2008) Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49:24S–42SPubMedCrossRef
20.
Semenza GL, Roth PH, Fang HM, Wang GL (1994) Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269:23757–23763PubMed
21.
Zhong H, De Marzo AM, Laughner E et al (1999) Overexpression of hypoxia-inducible factor 1 α in common human cancers and their metastasis. Cancer Res 59:5830–5835PubMed
22.
Robey IF, Lien AD, Welsh SJ et al (2005) Hypoxia inducible factor-1 alpha and the glycolytic phenotype in tumors. Neoplasia 7:324–330PubMedCrossRef
23.
Li J, Shi M, Cao Y et al (2006) Knockdown of hypoxia-inducible factor-1α in breast cancer cells results in reduced tumor growth and increased sensitivity to methotrexate. Biochem Biophy Res Commun 342:1341–1351CrossRef
24.
Burgman P, O’Donoghue JA, Humm JL, Ling CC (2001) Hypoxia-induced increases in FDG uptake in MCF 7 cells. J Nucl Med 42:170–175PubMed
25.
Liao D, Corle C, Seagroves TN, Johnson RS (2007) Hypoxia-inducible factor-1α is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 67:563–572PubMedCrossRef
26.
Toniolo PG, Levitz M, Zeleniuch-Jacquotte A et al (1995) A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 87:190–197PubMedCrossRef
27.
28.
Lareef MH, Garber J, Russo PA et al (2004) The estrogen antagonist ICI-182-780 does not inhibit the transformation phenotypes induced by 17-β-estradiol and 4-OH estradiol in human breast epithelial cells. Int J Oncol 26:423–429
29.
Russo J, Russo IH (2006) The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 102:89–96PubMedCrossRef
30.
Russo J, Fernandez SV, Russo PA et al (2006) 17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells. FASEB J 20:1622–1634PubMedCrossRef
31.
Shekhar MP, Nangia-Makker P, Wolman SR et al (1998) Direct action of estrogen on sequence of progression of human preneoplastic breast disease. Am J Pathol 152:1129–1132PubMed
32.
Yamaguchi Y (2007) Microenvironmental regulation of estrogen signals in breast cancer. Breast Cancer 14:175–181PubMedCrossRef
33.
Neeman M, Degani H (1989) Metabolic studies of estrogen and tamoxifen-treated human breast cancer cells by nuclear magnetic resonance spectroscopy. Cancer Res 49:589–594PubMed
34.
Rivenzon-Segal D, Boldin-Adamsky S, Seger D et al (2003) Glycolysis and glucose transporter 1 as markers of response to hormonal therapy in breast cancer. Int J Cancer 107:177–182PubMedCrossRef
35.
Meneses AM, Medina RA, Kato S et al (2008) Regulation of GLUT 3 and glucose uptake by cAMP signalling pathway in the breast cancer cell line ZR-75. J Cell Physiol 214:110–116PubMedCrossRef
36.
Kurebayashi J, Otsuki T, Moriya T, Sonoo H (2001) Hypoxia reduces hormone responsiveness of human breast cancer cells. Jpn J Cancer Res 92:1093–1101PubMedCrossRef
37.
Cooper C, Liu GY, Niu YL et al (2004) Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor α in human breast carcinoma. Clin Cancer Res 10:8720–8727PubMedCrossRef
38.
Russo J, Balogh GA, Chen J et al (2006) The concept of stem cell in mammary gland and its implication in morphogenesis, cancer and prevention. Front Biosci 11:151–172PubMedCrossRef
39.
Russo J, Lareef MH, Balogh G et al (2003) Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J Steroid Biochem Mol Biol 87:1–25PubMedCrossRef
40.
Russo J, Lareef MH, Tahin Q et al (2002) 17β-Estradiol is carcinogenic in human breast epithelial cells. J Steroid Biochem Mol Biol 80:149–162PubMedCrossRef
41.
Huang Y, Fernandez SV, Goodwin S et al (2007) Epithelial to mesenchymal transition in human breast epithelial cells transformed by 17beta-estradiol. Cancer Res 67:11147–11157PubMedCrossRef
42.
Miller FR (2000) Xenograft models of premalignant breast disease. J Mammary Gland Biol Neopl 5:379–391CrossRef
43.
Worsham MJ, Pals G, Schouten JP et al (2006) High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in MCF10 model. Breast Cancer Res Treat 96:177–186PubMedCrossRef
44.
Chen C, Pore N, Behrooz A et al (2001) Regulation of glut1 mRNA by Hypoxia- inducible factor-1. J Biol Chem 276:9519–9525PubMedCrossRef
45.
Blancher C, Moore JW, Robertson N, Harris AL (2001) Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1, HIF-2, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res 61:7349–7355PubMed
46.
Burnol AF, Leturque A, Loizeau M et al (1990) Glucose transporter expression in rat mammary gland. Biochem J 270:277–279PubMed
47.
Alo PL, Visca P, Botti C et al (2001) Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue. Am J Clin Pathol 116:129–134PubMedCrossRef
48.
Nguyen XC, So Y, Chung JH et al (2008) High correlations between primary tumours and loco-regional metastatic lymph nodes in non-small-cell lung cancer with respect to glucose transporter type 1-mediated 2-deoxy-2F18-fluoro-d-glucose uptake. Eur J Cancer 44:692–698PubMedCrossRef
49.
Zhou S, Wang S, Wu Q et al (2008) Expression of glucose transporter-1 and -3 in the head and neck carcinoma—the correlation of the expression with the biological behaviors. ORL J Otorhinolaryngol Relat Spec 70:189–194PubMedCrossRef
50.
Rogers S, Docherty SE, Slavin JL et al (2005) Differential expression of GLUT12 in breast cancer and normal breast tissue. Cancer Lett 193:225–233CrossRef
51.
Shi J, Simpkins JW (1997) 17 beta-Estradiol modulation of glucose transporter 1 expression in blood-brain barrier. Am J Physiol 272:E1016–E1022PubMed
52.
Macheda ML, Williams ED, Best JD et al (2003) Expression and localization of Glut1 and Glut 12 glucose transporters in the pregnant and lactating rat mammary gland. Cell Tissue Res 311:91–97PubMedCrossRef
53.
Russo J, Lareef H, Tahin Q, Russo IH (2002) Pathways of carcinogenesis and prevention in the human breast. Eur J Cancer 38:S31–S32PubMedCrossRef
54.
Russo J, Mailo D, Hu YF et al (2005) Breast differentiation and its implication in cancer prevention. Clin Cancer Res 11:931s–936sPubMed
55.
Rivenzon-Segal D, Rushkin E, Polak-Charcon S, Degani H (2000) Glucose transporters and transport kinetics in retinoic acid-differentiated T47D human breast cancer cells. Am J Physiol Endocrinol Metab 279:E508–E519PubMed
56.
Zhao F-Q, Keating AF (2007) Functional properties and genomics of glucose transporters. Curr Genomics 8:113–128PubMedCrossRef
57.
Godoy A, Ulloa V, Rodriguez F et al (2006) Differential subcellular distribution of glucose transporters Glut1-6 and Glut9 in human cancer: ultrastructural localization of Glut1 and Glut5 in breast tissues. J Cell Physiol 207:614–627PubMedCrossRef
58.
Medina RA, Meneses AM, Vera JC et al (2003) Estrogen and progesterone up-regulate glucose transporter expression in ZR-75-1 human breast cancer cells. Endocrinology 144:4527–4535PubMedCrossRef
59.
Medina RA, Meneses AM, Vera JC et al (2004) Differential regulation of glucose transporter expression by estrogen and progesterone in Ishikawa endometrial cancer cells. J Endocrinol 182:467–478PubMedCrossRef
60.
Ciardiello F, Tortora G (1998) Interactions between the epidermal growth factor receptor and Type I protein kinase A: biological significance and therapeutic implications. Clin Cancer Res 4:821–828PubMed
61.
Troyer K, Lee DC (2001) Regulation of mammary gland development and tumorigenesis by the ERBB signalling network. J Mammary Gland Biol Neoplasia 6:7–21PubMedCrossRef
62.
Nicholson RI, Hutcheson IR, Harper ME et al (2001) Modulation of epidermal growth factor receptor in endocrine- resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 8:175–182PubMedCrossRef
63.
Nicholson RI, Hutcheson IR, Britton JM et al (2005) Growth factor signalling networks in the breast cancer and resistance to endocrine agents: new therapeutic strategies. J Steroid Biochem Mol Biol 93:257–262PubMedCrossRef
64.
Murphy L, Cherlet T, Lewis A et al (2003) New insights into estrogen receptor function in human breast cancer. Ann Med 35:614–631PubMedCrossRef
65.
Likhite VS, Stossi F, Kim K et al (2006) Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 20:3120–3132PubMedCrossRef
66.
Lo HW, Hsu SC, Hung MC (2006) EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocation. Breast Cancer Res Treat 95:211–218PubMedCrossRef
67.
Peng XH, Karna P, Cao Z et al (2006) Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1α signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 281:25903–25914PubMedCrossRef
68.
Tortora G, Pepe S, Bianco C et al (1994) The RIα subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells. Oncogene 9:3233–3240PubMed
69.
Binder C, Binder L, Marx D et al (1997) Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues. Anticancer Res 17(6):4299–4304PubMed
70.
Young CD, Lewis AS, Rudolph MC et al (2011) Modulation of glucose transporter1 (Glut1) expression levels alters Mouse mammary tumor cell growth in vitro and in vivo. PLoS One 6(8):e23205PubMedCrossRef
71.
Rastogi S, Banerjee S, Chellappan S, Simon GR (2007) Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett 257:244–251PubMedCrossRef
Metadata
Title
Progressive increase of glucose transporter-3 (GLUT-3) expression in estrogen-induced breast carcinogenesis
Authors
M. A. Kocdor
H. Kocdor
J. S. Pereira
J. E. Vanegas
I. H. Russo
J. Russo
Publication date
01-01-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 1/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0882-3

Other articles of this Issue 1/2013

Clinical and Translational Oncology 1/2013 Go to the issue

Special Article

SEOM recommendations on the structure and operation of hereditary cancer genetic counseling units (HCGCUs)

Research Article

CD44+/CD24− breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties

Research Article

EGFR expression is linked to osteopontin and Nf-κB signaling in clear cell renal cell carcinoma

Educational Series – Red Series

Analysis of economic evaluations of pharmacological cancer treatments in Spain between 1990 and 2010

Research Article

Tumor bed segmentation: first step for partial breast irradiation

Educational Series – Blue Series

Next-generation sequencing reveals the secrets of the chronic lymphocytic leukemia genome
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits